Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-06-08
2010-12-21
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S006700, C514S006800, C514S006900
Reexamination Certificate
active
07855177
ABSTRACT:
Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
REFERENCES:
patent: 4608364 (1986-08-01), Grau et al.
patent: 4652548 (1987-03-01), Chance et al.
patent: 7323543 (2008-01-01), Van Antwerp et al.
patent: 2007015069 (2007-02-01), None
patent: 2008118387 (2008-03-01), None
patent: 2009068911 (2009-06-01), None
Kamikawa, A., et al, Proinsulin C-Peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats, Diabetes Metab Res Rev, 2008, 24(4), 331-8.
Hills, CE, Intracellular signaling by C-peptide, Exp Diab Res, 2008, Article ID 635158.
Nordquist, L,, Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications?, Vasc Health Risk Man, 2008, 4(6), 1283-1288.
Ekberg, K, C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy, J. Diabetes Care. 2007, 30(1), 71-6.
Zhang, W, C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats, Diabetes Metab Res Rev. 2007, 23(1), 63-70.
Vish, MG, Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice, Crit Care Med. 2007, 35 (5):1348-55.
Kamiya, H, et al, C-peptide reverses nociceptive neuropathy in Type I diabetes, Diabetes. 2006, 55, 3581-3587.
Shafqat, J, et al, Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects, Cell Mol Life Sci. 2006, 63 (15):1805-11.
Rebsomen, L, et al, C-peptide replacement improves weight gain and renal function in diabetic rats, Diabetes Metab. 2006, 32 (3), 223-8.
Wahren, J, et al, C-peptide: new findings and therapeutic implications in diabetes, Clin Physiol Funct Imaging, 2004, 24, 180-189.
Sato, Y, et al, C-peptide fragments stimulate glucose utilization in diabetic rats, Cell Mol Life Sci. 2004, 61(6), 727-32.
Johansson, BL, et al, C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients, J Physiol Endocrinol Metab, 2004, 286(1), E14-9.
Wahren, J, et al, Biological Effects of C-peptide and Proinsulin, Int. Textbook of Diabetes Mellitus, Third Edition, 2004.
Wahren, J, et al, C-peptide makes a comeback, Diab Met Res. 2003, 19, 345-347.
Cotter, MA, et al, Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition, Diabetes. 2003, 52(7), 1812-7.
Ekberg, K, et al, Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes, J. Diabetes. Feb. 2003;52(2), 536-41.
Hansen, A, C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes, Diabetes. Oct. 2002;51(10), 3077-82.
Forst, T, et al, Effect of C-peptide on glucose metabolism in patients with type 1 diabetes, Effect of C-peptide on glucose metabolism in patients with type 1 diabetes, Diabetes Care. 2002, 25(6), 1096-7.
Fernqvist-Forbes, E, et al, Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus, Acta Physiol Scand. 2001, 172(3), 159-65.
Zhang, W, et al, Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat, Int. J. Exp. Diabetes. Res. 2001, 2(3), 187-93.
Sima, AA, et al, Proinsulin C-peptide—A consensus statement, Int J Exp Diab Res. 2001, 2, 145-151.
Grunberger, G, et al, Molecular basis for the insulinomimetic effects of C-peptide, Diabetologia. 2001, 44, 1247-1257.
Sima, AA, et al, C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat, Diabetologia, 2001, 44(7), 889-97.
Johansson, BL, et al, Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus, J. Diabet Med. Mar. 2000;17(3), 181-9.
Li, L, et al, Rat C peptide I and II stimulate glucose utilization in STZ-induced diabetic rats, Diabetologia. 1999, 42(8), 958-64.
Johansson, BL, et al, C-peptide potentiates the vasoconstrictor effect of neuropeptide Y in insulin dependent diabetic patients, J. Acta Physiol Scand. 1999, 165, 39-44.
Oskarsson, P, et al, Effects of C-peptide on insulin-induced hypoglycaemia and its counterregulatory responses in IDDM patients, Diabet Med. Aug. 1997;14(8), 655-9.
Ido, Y, et al, Prevention of vascular and neural dysfunction in diabetic rats by C-peptide, Science. 1997, 277(5325), 563-6.
Johansson, BL, C-peptide improves autonomic nerve function in IDDM patients, Diabetologia. 1996, 39(6), 687-95.
Wu, W, Effect of C-peptide administration on whole body glucose utilization in STZ-induced diabetic rats, Acta Physiol Scand. 1996, 157(2), 253-8.
Zierath, JR, et al, C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation, Diabetologia. 1996, 39, 306-13.
Zierath, JR, et al, In vitro studies of skeletal muscle: Hormonal and metabolic regulation of glucose transport, Acta Physiol Scand. 1995, 155 (Suppl. 626), 11-96.
Johansson, BL, et al, Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1, J Clin Endocrinol Metab. 1993, 77(4), 976-81.
Johansson, BL, et al, Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients, Diabetologia. Dec. 1992;35(12), 1151-8.
Johansson, BL, et al, The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients, Diabetologia. 1992, 35(2), 121-8.
Sjoberg, S, et al, Renal and splanchnic exchange of human biosynthetic C-peptide in type 1 (insulin-dependent) diabetes mellitus, Diabetologia. Jun. 1991;34(6), 423-8.
Zierath, JR, et al, Effect of human C-peptide on glucose transport in in vitro incubated human skeletal muscle, Diabetologia. 1991, 34(12), 899-901.
Schatz, H, et al, Bioactivity and pharmacokinetics of human proinsulin in comparison to human insulin after intravenous and subcutaneous injection, Horm Metab Res. Jul. 1988;20(7), :445-9.
Wojcikowski, C, et al, Effects of synthetic rat C-peptide in normal and diabetic rats, Diabetologia. Sep. 1983;25(3), 288-90.
Meyer, J.A., et al, Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter, Diabetologia, 51, 175-182, 2008.
Kamiya, H., et al, The beneficial effects of C-peptide on Diabetic polyneuropathy, Rev. Diabet. Stud., 6 (3), 187-202, 2009.
Wahren, J., et al, C-peptide is relevant in type 1 diabetes and its complications: Summary and Conclusions to the Special Issue, Rev. Diabet. Stud., 6 (3), 223-224, 2009.
Learning to live well with diabetes, Ed. Cheryl Weiler , DCI Publishing, Minneapolis (1991).
American Diabetes association complete guide to diabetes. American Diabetes Association, Alexandria, VA (1996).
Callaway James
Ekberg Karin
Wahren John
Bennett Dennis A.
Cebix Inc.
Cubitt Andrew
Ha Julie
LandOfFree
Methods and kits for preventing hypoglycemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and kits for preventing hypoglycemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and kits for preventing hypoglycemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208588